In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 658 ( 2022-08-17)
Abstract:
Despite the success of the first SARS-CoV-2 vaccines, additional vaccines are essential for responding to variants of concern. Here, Arunachalam et al. tested the durability of immune responses elicited by a SARS-CoV-2 subunit nanoparticle vaccine. This vaccine was composed of the receptor binding domain (RBD) of the ancestral strain of SARS-CoV-2 and was adjuvanted with AS03. Two immunizations with the vaccine resulted in durable, but not cross-reactive, immunity in nonhuman primates (NHPs); further boosting with a version of the vaccine containing the Beta variant or the ancestral RBD elicited cross-reactive immune responses that conferred protection against Omicron challenge in the NHPs. These data suggest that vaccines derived from different SARS-CoV-2 variants may elicit cross-reactive protection.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abq4130
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink